Beyond Air, Inc. (XAIR)
| Market Cap | 29.10M |
| Revenue (ttm) | 2.34M |
| Net Income (ttm) | -55.49M |
| Shares Out | 72.19M |
| EPS (ttm) | -1.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 507,965 |
| Open | 0.420 |
| Previous Close | 0.416 |
| Day's Range | 0.403 - 0.438 |
| 52-Week Range | 0.296 - 2.360 |
| Beta | -0.23 |
| Analysts | Strong Buy |
| Price Target | 3.67 (+810.44%) |
| Earnings Date | Feb 10, 2025 |
About XAIR
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the t... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for XAIR stock is "Strong Buy." The 12-month stock price forecast is $3.67, which is an increase of 810.44% from the latest price.
News
National Advertising Division Recommends Beyond Air Discontinue or Modify Comparative Safety Claims for its iNO Products
In a Fast-Track SWIFT challenge brought by competitor Vero Biotech, Inc., BBB National Programs' National Advertising Division recommended that Beyond Air, Inc. discontinue the challenged comparative ...
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
HAMILTON, Bermuda, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for soli...
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery
NeuroNOS Appoints Nobel Laureate, Roger D. Kornberg, to Scientific Advisory Board
Professor Kornberg will assist in accelerating the development of treatments for Autism Spectrum Disorder and potentially other neurological disorders Professor Kornberg will assist in accelerating th...
Beyond Air to Participate in the Piper Sandler 36th Annual Healthcare Conference
GARDEN CITY, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air, Inc. (XAIR) Q2 2025 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR) Q2 2025 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Ex...
Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
Revenues increased 17% compared to the previous quarter ended June 30, 2024 Strengthened balance sheet is expected to provide sufficient cash runway through June 2026 Completed a $20.6 million private...
Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Cancer to Present Preclinical Data of Ultra-High Concentration Nitric Oxide (UNO) Low Volume Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
HAMILTON, Bermuda, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for soli...
Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated Delivery Networks
Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems Revolutionary inhaled nitric oxide technology set to reach broader healthcare systems
Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group –
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt fr...
Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia
GARDEN CITY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024
GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessi...
Beyond Air, Inc. (XAIR) Q4 2024 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR) Q4 2024 Earnings Call Transcript June 24, 2024 4:30 PM ET Company Participants Garth Russell - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Exec...
Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth expected to accelerate each quarter going forward F...
Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Beyond Air® Appoints David Webster as Chief Commercial Officer
Mr. Webster brings more than 20 years of executive level experience in the life sciences industry Mr. Webster brings more than 20 years of executive level experience in the life sciences industry
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
– Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation der...
Beyond Air® Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessi...
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript
Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript